<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363389">
  <stage>Registered</stage>
  <submitdate>14/12/2012</submitdate>
  <approvaldate>17/12/2012</approvaldate>
  <actrnumber>ACTRN12612001301853</actrnumber>
  <trial_identification>
    <studytitle>Investigating the effectiveness of Elderberry capsules in the prevention of upper respiratory symptoms associated with long distance travel.</studytitle>
    <scientifictitle>Randomised, double-blind, placebo-controlled trial of Elderberry supplementation preventing upper respiratory symptoms in air travellers.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Upper respiratory symptoms</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Elderberry capsules (active) are 300mg of standardised Elderberry membrane filtered extract powder (22% polyphenols, 15% anthocyanins) and 150mg of rice flour. Participants will take 2 capsules per 24 hour period for 10 days prior to travel, 3 capsules per 24 hour during travel and a further 4 days at their destination. Trial participation lasts 16 days including the first 4 or 5 days on arriving at their destinations. Travel duration will differ between participants and should not exceed 72 hours of travel. Travel duration is defined as leaving home to arriving at the accommodation at the destination.</interventions>
    <comparator>Placebo capsules comprises of 350mg of rice flour and 100mg of iron (III) oxide (red) and are appearance matched to the active capsules but will not contain any active Elderberry ingredients. Dosing and duration will be the same as the intervention.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Active vs Placebo Group comparison for the number of participants suffering from upper respiratory symptoms - using Jackson Score.</outcome>
      <timepoint>Daily (16 days participation)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Active vs Placebo group comparison in Quality of Life and upper respiratory symptoms using SF-12 cute and WURSS-21 surveys. </outcome>
      <timepoint>1) Baseline (Day 1)
2) 2 days prior to travel
3) End of trial participation (Day 16)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Level of Stress prior to the commencement of trial using Perceived Stress Scale (PSS) survey</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) travelling a minimum of 7 hours flight 2) travelling via economy class 3) planning a minimum stay of 4 days at destination </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1) Diagnosed respiratory disease
2) Lactation or pregnancy
3) Pollen/plant allergy
4) Serious inflammatory or immunological conditions</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Concealed allocation is prepared by a statistician not involved in the study. A randomization schedule is prepared using a random number generated by computer prior to the enrolment of the first participant. Another person not involved in the study placed randomized numbers into opaque envelopes. The assignments were placed in sealed opaque numbered envelopes prior to the onset of the study and treatments determined after the baseline assessments had been completed. Each person who met the eligibility criteria was given the next opaque envelope treatment in sequential order. </concealment>
    <sequence>Random order generation using a computer generated program.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>25/02/2013</anticipatedstartdate>
    <actualstartdate>26/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>10/12/2014</actualenddate>
    <samplesize>280</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,SA,TAS,WA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Griffith University</primarysponsorname>
    <primarysponsoraddress>170 Kessels Road
Nathan
QLD 4111</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Iprona AG</fundingname>
      <fundingaddress>Industriestrasse
Via Industria 1/6
I-39011 LANA (BZ)
</fundingaddress>
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will investigate the effectiveness of Elderberry lozenges in the prevention of upper respiratory symptoms associated with long distance travel.</summary>
    <trialwebsite>http://www.griffith.edu.au/health/school-pharmacy/research/elderberry-clinical-trial</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Griffith University Human Research Ethics Committee</ethicname>
      <ethicaddress>170 Kessels Road
Nathan
QLD 4111</ethicaddress>
      <ethicapprovaldate>18/12/2012</ethicapprovaldate>
      <hrec>PHM/08/12/HREC</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Evelin Tiralongo</name>
      <address>School of Pharmacy
Griffith University
Gold Coast campus
QLD 4222</address>
      <phone>+61 (0) 7 5552 7098</phone>
      <fax />
      <email>e.tiralongo@griffith.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Evelin Tiralongo</name>
      <address>School of Pharmacy
Griffith University
Gold Coast campus
QLD 4222</address>
      <phone>+61 (0) 7 5552 7098</phone>
      <fax />
      <email>e.tiralongo@griffith.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Evelin Tiralongo</name>
      <address>School of Pharmacy
Griffith University
Gold Coast campus
QLD 4222</address>
      <phone>+61 (0) 7 5552 7098</phone>
      <fax />
      <email>e.tiralongo@griffith.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Shirley Wee</name>
      <address>School of Pharmacy
Griffith University
Gold Coast campus
QLD 4222</address>
      <phone>+61 (0) 7 5552 8131</phone>
      <fax />
      <email>s.wee@griffith.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>